Dexcom (DXCM) AI Stock Analysis

• Market Cap: $24.72B
• Dividend Yield: N/A
• Average Volume (3M): 4.57M
• Price to Earnings (P/E): 31.0
• Beta (1Y): 1.14
• Revenue Growth: 14.21%
• EPS Growth: 5.66%
• Country: US
• Employees: 10,200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.68
• Shares Outstanding: 384,864,840
• 10 Day Avg. Volume: 3,840,960
• 30 Day Avg. Volume: 4,570,244
• PEG Ratio: 0.66
• Price to Book (P/B): 9.43
• Price to Sales (P/S): 5.56
• P/FCF Ratio: 24.04
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 5.48
• Enterprise Value/Gross Profit: 9.11
• Enterprise Value/Ebitda: 19.10
• 1Y Price Target: $86.76
• Price Target Upside: 35.06% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 20
• EPS Forecast (FY): 2.49
• Revenue Forecast (FY): $5.23B

• Rating: 77 Outperform
• Price Target: $73.00 ▲(13.64% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

DXCM scores well on financial performance (strong growth, profitability, and improved leverage) and is supported by upbeat 2026 guidance emphasizing margin expansion and product catalysts. The overall score is tempered by premium valuation (P/E ~35) and a mixed longer-term technical backdrop with the 200-day average slightly above the current price.

Positive Factors

Recurring consumable revenue model

Dexcom’s core business is recurring consumables—disposable sensors and periodic transmitters—creating predictable, repeat purchase revenue and high lifetime value per patient. This model supports durable revenue visibility, aids reimbursement negotiations, and anchors long-term cash generation as installed base grows.

Strong cash generation and improved leverage

Material free cash flow and a meaningful reduction in leverage provide financial flexibility for R&D, manufacturing investment, and capital returns. A stronger balance sheet reduces refinancing risk, funds product rollouts and the Ireland ramp, and improves resilience to reimbursement or pricing headwinds over the medium term.

Product innovation & G7 15‑day rollout

G7 15‑day’s improved accuracy and longer wear materially enhance the value proposition versus competitors, supporting higher retention, potential unit economics improvements, and incremental margin as manufacturing efficiencies scale. Combined with Smart Basal and EHR integrations, this deepens clinical stickiness and partner integrations long-term.

Negative Factors

Prior supply & sensor deployment issues

Historic supply, warranty and scrap problems materially affected results in 2025 and show the company’s operations remain sensitive to manufacturing and logistics execution. Recurrence or new manufacturing issues during product transitions could impair margins and delay patient access for multiple quarters.

Ramp-related OpEx from Ireland manufacturing

Bringing a new facility online requires upfront validation, hiring, and expense that will depress near-term operating leverage. Until production shifts from expensed ramp costs to lower-cost COGS, margins and free cash flow can be pressured, making execution timing a key multi-quarter risk to guided margin improvement.

Medicare timing & competitive pricing pressure

Uncertain CMS timing and potential competitive bidding could slow covered-life expansion or compress pricing. Strong competitors and PBM dynamics create persistent reimbursement and mix risk that can erode ASPs and growth cadence, making topline and margin outcomes contingent on multi‑party policy and contracting outcomes.

Dexcom Business Overview & Revenue Model

Company Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

How the Company Makes Money

Dexcom primarily makes money by selling CGM hardware and related supplies on a recurring-use model. The core revenue stream is product revenue from (1) disposable CGM sensors that are replaced regularly, and (2) CGM transmitters and/or compatible hardware that are replaced periodically depending on product design and lifecycle. This creates ongoing demand from existing users in addition to new patient starts. Dexcom also earns revenue through distribution channels that include sales to third-party distributors and pharmacies as well as direct or contracted fulfillment to patients, with reimbursement commonly coming from private insurers and government healthcare programs where coverage applies. A significant earnings driver is interoperability and partnerships with insulin delivery and diabetes-management ecosystem players: Dexcom’s CGM systems are designed to integrate with certain insulin pumps, automated insulin delivery (AID) systems, and digital health applications, which can support adoption and persistence, though Dexcom’s revenue is still primarily tied to sales of its CGM consumables and related hardware. Specific partnership financial terms (e.g., revenue sharing, minimum commitments) are not publicly available in sufficient detail here and are therefore null.

Dexcom Financial Statement Overview

Summary

Strong fundamentals supported by steady multi-year revenue expansion to $4.66B (2025), healthy profitability (about 60% gross margin and ~18% net margin in 2025), and improved leverage in 2025 (debt-to-equity ~0.51). Free cash flow exceeded $1.0B in 2025, but margin stability and cash conversion versus net income have been uneven across years.

Income Statement

Revenue expanded steadily from $1.93B (2020) to $4.66B (2025), with a notably strong step-up in 2025 versus 2024. Profitability is healthy for the industry: 2025 gross margin was ~60% and net margin was ~18%, with operating profitability also solid. The main weakness is margin variability over time (gross margin trending lower versus earlier years and net margin swinging sharply in 2020), which suggests earnings quality and cost structure have not been perfectly stable across the cycle.

Balance Sheet

Leverage improved meaningfully in 2025, with debt-to-equity dropping to ~0.51 from ~1.23 in 2024, supported by a higher equity base and lower debt. Returns on shareholder capital are strong (ROE ~30% in 2025), indicating efficient capital use. The key risk is that leverage was elevated for several years prior to 2025 (debt-to-equity ~1.0–1.25), so the balance sheet story is improved but not consistently conservative across the full period.

Cash Flow

Cash generation strengthened materially: operating cash flow rose to ~$1.44B and free cash flow to ~$1.08B in 2025, with healthy growth versus 2024. Free cash flow has improved substantially from the very low 2021 level, supporting reinvestment and balance sheet flexibility. Offsetting this, cash conversion versus accounting earnings is not consistently strong (free cash flow running below net income each year shown), and the operating cash flow-to-net-income relationship has been uneven across years.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.66B	4.03B	3.62B	2.91B	2.45B
Gross Profit	2.80B	2.44B	2.29B	1.88B	1.68B
EBITDA	1.16B	945.70M	916.70M	565.30M	377.50M
Net Income	836.30M	576.20M	541.50M	341.20M	216.90M
Balance Sheet
Total Assets	6.34B	6.48B	6.26B	5.39B	4.93B
Cash, Cash Equivalents and Short-Term Investments	2.00B	2.58B	2.72B	2.46B	2.73B
Total Debt	1.39B	2.59B	2.59B	2.15B	2.16B
Total Liabilities	3.59B	4.38B	4.20B	3.26B	2.89B
Stockholders Equity	2.75B	2.10B	2.07B	2.13B	2.04B
Cash Flow
Free Cash Flow	1.08B	630.70M	511.90M	304.70M	53.30M
Operating Cash Flow	1.44B	989.50M	748.50M	669.50M	442.50M
Investing Cash Flow	536.00M	-207.50M	-507.20M	-521.50M	-216.10M
Financing Cash Flow	-1.69B	-734.80M	-318.60M	-552.50M	10.40M

Dexcom Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 64.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DXCM, the sentiment is Negative. The current price of 64.24 is below the 20-day moving average (MA) of 70.84, below the 50-day MA of 70.53, and below the 200-day MA of 73.03, indicating a bearish trend. The MACD of -1.26 indicates Positive momentum. The RSI at 29.93 is Positive, neither overbought nor oversold. The STOCH value of 3.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DXCM.

Dexcom Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	77 Outperform	$24.72B	30.97	32.44%	―	14.21%	5.66%
EW	75 Outperform	$47.52B	46.44	10.39%	―	0.19%	65.58%
SNN	72 Outperform	$14.03B	22.70	9.20%	2.28%	5.78%	61.52%
STE	69 Neutral	$21.04B	32.31	10.21%	0.94%	5.15%	60.30%
PODD	68 Neutral	$15.48B	80.92	17.36%	―	27.12%	-41.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNDM	45 Neutral	$1.48B	-7.22	-141.98%	―	17.87%	-57.03%

Dexcom Corporate Events

Dexcom Executive Chairman Kevin Sayer Returns From Leave

Dexcom announced that long-time leader Kevin R. Sayer, who had informed the board in July 2025 of his plan to retire as chief executive officer effective January 1, 2026, was appointed executive chairman of the board as of that same date to provide ongoing leadership and strategic guidance. The move marks a transition from his CEO role while retaining his influence over the company’s direction and continuity at the board level.

After taking a temporary leave of absence effective September 14, 2025, Sayer notified Dexcom on February 27, 2026, that he would return from leave on March 2, 2026, at which point he resumed his duties as executive chairman and Mark Foletta returned to his role as lead independent director. On the same date, Sayer entered into a letter agreement setting an annual base salary of $610,000 and granting him restricted stock units valued at $2.35 million that vest on March 8, 2027, while he remains eligible for standard executive benefits but no longer participates in the company’s severance and change-in-control plan, clarifying his long‑term incentives and governance role for investors and other stakeholders.

The most recent analyst rating on (DXCM) stock is a Buy with a $83.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.

Dexcom Adds Google Executive Rick Osterloh to Board

On February 26, 2026, Dexcom’s board expanded to twelve members and appointed Rick Osterloh, Google’s Senior Vice President for Platforms & Devices, as an independent director with a term running until the 2026 annual shareholder meeting. He joins the Compensation and Technology committees, receives standard director indemnification, and was granted restricted stock units under Dexcom’s non-employee director compensation program, aligning his incentives with long-term shareholder interests.

Osterloh’s appointment brings deep expertise in consumer hardware, platforms, and large-scale product operations from his leadership roles at Google, Motorola, and other major technology firms. Dexcom’s leadership highlighted that his experience integrating advanced hardware, software, and AI should support the company’s long‑term product strategy in biosensing and metabolic health, potentially strengthening its innovation pipeline and competitive position in digital health and wearables.

The most recent analyst rating on (DXCM) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.

Dexcom Names Jacob Leach as Incoming Chief Executive

Dexcom’s board has confirmed that President and Chief Operating Officer Jacob S. Leach will assume the roles of President, Chief Executive Officer and director effective January 1, 2026, following the previously announced resignation of long-time CEO Kevin R. Sayer as of that date. On December 19, 2025, Leach agreed to an offer package that includes a $1,150,000 annual base salary, a target annual bonus equal to 150% of base pay, $7.5 million in time-vested restricted stock units over three years, and $7.5 million in performance stock units contingent on meeting compensation committee–set performance goals, while remaining eligible for existing executive severance and benefit plans; the board expects Sayer to return from medical leave around March 2026 to resume his role as board chairman, with Mark Foletta serving as interim chair in the meantime, signaling continuity in the company’s leadership transition and governance structure.

The most recent analyst rating on (DXCM) stock is a Buy with a $78.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.